Deloitte.

Extending ACHILLES to Enable Automated Data Characterization of Clinical Trials Data

May 17, 2016

Introduction

OHDSI

OBSERVATIONAL HEALTH DATA SCIENCES AND INFORMATICS

Who We Are | Who We Serve | Data Standardization | Software Tools | Resources | Join the Journey | Events

Home › Who We Are › Collaborators › Kristin Feeney

Kristin Feeney

Bio | OHDSI Publications

Kristin Feeney, MPH
Product Development Consultant, Translational Research and Real World Evidence
ConvergeHEALTH by Deloitte
krfeeney@deloitte.com

Kristin is a Consultant for the ConvergeHEALTH by Deloitte division of Deloitte Consulting. She specializes in computational epidemiology for real world evidence generation and translational research.

Kristin is currently a collaborator with the symposium organizing committee working group in OHDSI and regularly attends community calls. Her Deloitte team is actively exploring ways to expand the use cases that OHDSI applications address.

Kristin holds a Bachelor's degree in Exercise Science from Elon University and a Master's in Public Health in Epidemiology from Boston University School of Public Health.

Prior to joining Deloitte, Kristin ran more than a dozen Phase 1-4 NIH, industry and physician-led cardiovascular clinical trials at a Harvard Medical School affiliated Academic Medical Center. Following her research tenure, she completed a post-graduate rotation with a Nationwide Accountable Care Act Medicare Demonstration Project mining real world health plan payer and provider data to improve Medicare Risk Adjustment program management.

Collaborator page: http://www.ohdsi.org/who-we-are/collaborators/kristin-feeney/

Deloitte's Life Sciences & Health Care Practice includes 9,000 practitioners in 90+ countries.

*We are serving **leading companies** across the health care value chain with an **unparalleled "ecosystem" view**.*

Life Sciences

- 71% of the 2014 Fortune Global 500 LSHC companies
- Nearly 95% of the Fortune U.S. 500 LSHC companies
- 10 of the 10 largest global pharma manufacturers
- 8 of the 10 largest global biotechnology companies
- 10 of the 10 largest global medical equipment manufacturers
- Leading health care distributors around the world

Health Care

Payers

- Nearly 85% of the Top 25 U.S. Health Plans (as ranked by AIS's Directory of Health Plans)
- Nearly 60% of the Nation's Blue Cross Blue Shield Plans

Providers

- Over 80% of Honor Roll Hospitals (U.S. News & World Report)
- 9 of the 10 Largest Health care Systems (Mdrn Hthcre)
- 4 of the 5 Largest For-Profit Healthcare Systems (Modern Healthcare)
- 10 of the 10 Largest Catholic Healthcare Systems (Modern Healthcare)
- 60% of the Major Teaching Hospitals (Thomson Reuters 100 Top Hospitals)

Government Health

- Largest departments and ministries of health in all of the leading 25 nations as ranked by World Economic Forum (e.g., UK, FR, DE, CA, AU, IN, IL)
- US Federal Health agencies: HHS, CDC, CMS, FDA, IHS, NIH, VA, Defense Health
- >30 US state government Health & Human Services agencies

ConvergeHEALTH by Deloitte.

Innovation unit focused on applied analytics to enable value based, personalized care.

Deloitte.Technology

Transforming business with technology

Over 30,000 practitioners across industries in over 100 countries.

Deloitte @ BioIT World 2016

Track 7 – Clinical Research & Translational Informatics

Luncheon Presentation II: Accelerating Insights in Translational Research: Self-Service Analytics and Visualizations at Amgen

George Seegan, Ph.D., Research & Development Informatics, Amgen

David Hardison, Ph.D., Vice President, Health Sciences, ConvergeHEALTH by Deloitte





Track 11 – Open Source Innovations, Poster

Why Extend ACHILLES?

To leverage OHDSI analytics applications an organization must transform the structure of its data from its native format to the OMOP CDM. This can be a substantial investment for an organization and has some limitations:

- The OMOP CDM is optimized for observational data sets. As such, it is only partially suited to absorb clinical trial data attributes (i.e. adverse events, drug exposures).
- The OMOP CDM can retain the relationship between facts stored as records in a table called FACT_RELATIONSHIP. Detailing all of the relationships captured in study metadata requires shoehorning and stretching the OMOP vocabulary to adapt to the nuances of clinical trials data.
- The visualizations deployed in ACHILLES are not optimized for experimental data. An out of the box deployment of ACHILLES lacks a report to characterize key clinical trials data such as specimens and biomarker data.

Demo